ClinicalTrials.gg
Active, not recruitingNCT06282549Updated Nov 19, 2024

Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension

An observational study in Essential Hypertension, sponsored by Yuhan Corporation. Active, not recruiting at 5 sites in Korea, Republic of. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-11-19.

Sponsored by Yuhan Corporation · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,219
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies in Essential Hypertension by Yuhan Corporation — 2 open to participants now, 4 under way, 2 of them phase 3. Essential Hypertension · Yuhan Corporation.

Started
2022
the only one that year
Observational
Only one
of the 10
Registered
5th of 10
by date

Among the 10 studies in Essential Hypertension by Yuhan Corporation, this one is the only one that started in 2022, is the only observational one, and was the 5th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

2 of the 10 studies in Essential Hypertension by Yuhan Corporation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Essential Hypertension by Yuhan Corporation, or all of them as a file.
02

Study summary

This study is to develop a predictive model for cardiocerebrovascular risk factors in elderly patients with essential hypertension with Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination.

Read the detailed description

This is a phase IV, open-label, prospective, long-term cohort, observational study to identify the predictive model of cardiocerebrovascular risk factors in elderly patients with more than three antihypertensive agents in patients with essential hypertension in Korea.

03

Conditions studied

  • Essential Hypertension

Keywords

  • Telmisartan/Amlodipine/Chlorthalidone Fixed-Dose Combination (Truset)
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients in General Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A patient over 65-year-old with essential hypertension
  2. A patient with essential hypertension who require treatment with 3 or more antihypertensive medication, as determined by investigator's decision
  3. A patient with no MACCE within 6 months prior to the enrollment
  4. A patient who voluntarily signed the form

Exclusion criteria

Exclusion Criteria:

  1. A patient who participates in clinical trial
  2. A patient who are for the Truset tablet according to the label.
  3. A patient who is unable to complete the study judged by the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,219 participants (actual)
Patient registry
No

Interventions

  • DrugTelmisartan/Amlodipine/Chlorthalidone(Truset)

    Drug pages: Telmisartan · Amlodipine · Chlorthalidone

    Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg or Telmisartan/Amlodipine/Chlorthalidone 80/5/12.5 mg or Telmisartan/Amlodipine/Chlorthalidone 80/5/25 mg

06

What researchers measure

Primary outcomes

  1. Percentage of MACCE(Major Adverse Cardiovascular and Cerebrovascular Events)

    Percentage of MACCE(Major Adverse Cardiovascular and Cerebrovascular Events) after treatment at 12, 24 and 36months if applicable

    Time frame: 12, 24 and 36months

Secondary outcomes

  1. Percentage of MACCE(Major Adverse Cardiovascular and Cerebrovascular Events) in patients with asymptomatic target organ damage

    Percentage of MACCE(Major Adverse Cardiovascular and Cerebrovascular Events) in patients with asymptomatic target organ damage after treatment at 12, 24 and 36months if applicable

    Time frame: 12, 24 and 36months

  2. Mean Systolic Blood Pressure (MSBP)/ Diastolic Blood Pressure (MDBP)

    To evaluate change from baseline in Mean Systolic Blood Pressure (MSBP)/ Diastolic Blood Pressure (MDBP) measured by the Institution at 12, 24 and 36months if applicable

    Time frame: 12, 24 and 36months

  3. Patients Achieving the treatment goal in Mean Systolic Blood Pressure (MSBP)

    To evaluate the percentage of patients who reached the treatment goal for Mean Sitting Blood Pressure (MSBP) \< 140/90 mmHg measured by the Institution at 12, 24 and 36months if applicable

    Time frame: 36months

  4. Percentage of patients who terminated the treatment

    To evaluate the percentage of patients who terminated the treatment before 36 months

    Time frame: 36months

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Mar 2027, 57 months after the start.

Of 27 observational studies under Essential Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 52. This study's planned 57 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2024
First posted
Feb 28, 2024
StartActual
Jun 8, 2022
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Nov 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06282549
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Jun 8, 2022
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Nov 19, 2024

Study contacts

Changhoon Lee
principal investigator · Veterans Health Service Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion